{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:42:50Z","timestamp":1793997770856,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biomed Eng"],"DOI":"10.1038\/s41551-020-0597-7","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T12:03:30Z","timestamp":1597061010000},"page":"1090-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":308,"title":["Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel"],"prefix":"10.1038","volume":"4","author":[{"given":"Feihu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-4022","authenticated-orcid":false,"given":"Wenbing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8217-0307","authenticated-orcid":false,"given":"Zongyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb F.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-9767","authenticated-orcid":false,"given":"Fengyi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4684-2655","authenticated-orcid":false,"given":"Honggang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"597_CR1","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal, R. E. et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828\u2013833 (2010).","journal-title":"J. Immunother."},{"key":"597_CR2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"597_CR3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","volume":"29","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29, 285\u2013296 (2016).","journal-title":"Cancer Cell"},{"key":"597_CR4","first-page":"328rv324","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).","journal-title":"Sci. Transl. Med."},{"key":"597_CR5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"597_CR6","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014\u20131022 (2013).","journal-title":"Nat. Immunol."},{"key":"597_CR7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"597_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"597_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2015.12.003","volume":"39","author":"AM Cook","year":"2016","unstructured":"Cook, A. M., Lesterhuis, W. J., Nowak, A. K. & Lake, R. A. Chemotherapy and immunotherapy: mapping the road ahead. Curr. Opin. Immunol. 39, 23\u201329 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"597_CR10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"597_CR11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","volume":"15","author":"GN Barber","year":"2015","unstructured":"Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760\u2013770 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"597_CR12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2016.12.028","volume":"75","author":"T Rivera Vargas","year":"2017","unstructured":"Rivera Vargas, T., Benoit-Lizon, I. & Apetoh, L. Rationale for stimulator of interferon genes-targeted cancer immunotherapy. Eur. J. Cancer 75, 86\u201397 (2017).","journal-title":"Eur. J. Cancer"},{"key":"597_CR13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674\u2013678 (2008).","journal-title":"Nature"},{"key":"597_CR14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.1229963","volume":"339","author":"J Wu","year":"2013","unstructured":"Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826\u2013830 (2013).","journal-title":"Science"},{"key":"597_CR15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature12306","volume":"498","author":"A Ablasser","year":"2013","unstructured":"Ablasser, A. et al. cGAS produces a 2\u2032-5\u2032-linked cyclic dinucleotide second messenger that activates STING. Nature 498, 380\u2013384 (2013).","journal-title":"Nature"},{"key":"597_CR16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788\u2013792 (2009).","journal-title":"Nature"},{"key":"597_CR17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786\u2013791 (2013).","journal-title":"Science"},{"key":"597_CR18","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989\u20132003 (2011).","journal-title":"J. Exp. Med."},{"key":"597_CR19","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells. J. Exp. Med. 208, 2005\u20132016 (2011).","journal-title":"J. Exp. Med."},{"key":"597_CR20","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.bbrc.2016.09.021","volume":"478","author":"K Takashima","year":"2016","unstructured":"Takashima, K. et al. STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation. Biochem. Biophys. Res. Commun. 478, 1764\u20131771 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"597_CR21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus, A. et al. Tumor-derived cGAMP Triggers a STING-Mediated interferon response in non-tumor cells to activate the NK cell response. Immunity 49, 754\u2013763 (2018).","journal-title":"Immunity"},{"key":"597_CR22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018\u20131030 (2015).","journal-title":"Cell Rep."},{"key":"597_CR23","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","volume":"112","author":"O Demaria","year":"2015","unstructured":"Demaria, O. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl Acad. Sci. USA 112, 15408\u201315413 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"597_CR24","first-page":"283ra252","volume":"7","author":"J Fu","year":"2015","unstructured":"Fu, J. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 7, 283ra252 (2015).","journal-title":"Sci. Transl. Med."},{"key":"597_CR25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-16-0104","volume":"4","author":"E Moore","year":"2016","unstructured":"Moore, E. et al. Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol. Res. 4, 1061\u20131071 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"597_CR26","doi-asserted-by":"crossref","first-page":"1600013","DOI":"10.1002\/adbi.201600013","volume":"1","author":"ST Koshy","year":"2017","unstructured":"Koshy, S. T., Cheung, A. S., Gu, L., Graveline, A. R. & Mooney, D. J. Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy. Adv. Biosyst. 1, 1600013 (2017).","journal-title":"Adv. Biosyst."},{"key":"597_CR27","doi-asserted-by":"crossref","first-page":"eaar1916","DOI":"10.1126\/scitranslmed.aar1916","volume":"10","author":"CG Park","year":"2018","unstructured":"Park, C. G. et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10, eaar1916 (2018).","journal-title":"Sci. Transl. Med."},{"key":"597_CR28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","volume":"14","author":"D Shae","year":"2019","unstructured":"Shae, D. et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14, 269\u2013278 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"597_CR29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0167-4781(98)00132-8","volume":"1400","author":"DA Burden","year":"1998","unstructured":"Burden, D. A. & Osheroff, N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400, 139\u2013154 (1998).","journal-title":"Biochim. Biophys. Acta"},{"key":"597_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb07020.x","volume":"922","author":"LF Liu","year":"2000","unstructured":"Liu, L. F. et al. Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 922, 1\u201310 (2000).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"597_CR31","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.4049\/jimmunol.1401337","volume":"193","author":"J Ahn","year":"2014","unstructured":"Ahn, J., Ruiz, P. & Barber, G. N. Intrinsic self-DNA triggers inflammatory disease dependent on STING. J. Immunol. 193, 4634\u20134642 (2014).","journal-title":"J. Immunol."},{"key":"597_CR32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","volume":"39","author":"L Zitvogel","year":"2013","unstructured":"Zitvogel, L., Galluzzi, L., Smyth, M. J. & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74\u201388 (2013).","journal-title":"Immunity"},{"key":"597_CR33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/COC.0b013e3182a790ea","volume":"38","author":"G Lombardi","year":"2015","unstructured":"Lombardi, G. et al. Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study. Am. J. Clin. Oncol. 38, 514\u2013519 (2015).","journal-title":"Am. J. Clin. Oncol."},{"key":"597_CR34","doi-asserted-by":"crossref","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","volume":"8","author":"D Mathios","year":"2016","unstructured":"Mathios, D. et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci. Transl. Med. 8, 370ra180 (2016).","journal-title":"Sci. Transl. Med."},{"key":"597_CR35","doi-asserted-by":"crossref","first-page":"eaan3682","DOI":"10.1126\/scitranslmed.aan3682","volume":"10","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci. Transl. Med. 10, eaan3682 (2018).","journal-title":"Sci. Transl. Med."},{"key":"597_CR36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","volume":"16","author":"KN Sugahara","year":"2009","unstructured":"Sugahara, K. N. et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16, 510\u2013520 (2009).","journal-title":"Cancer Cell"},{"key":"597_CR37","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1039\/C3CC49453E","volume":"50","author":"AG Cheetham","year":"2014","unstructured":"Cheetham, A. G., Ou, Y. C., Zhang, P. & Cui, H. Linker-determined drug release mechanism of free camptothecin from self-assembling drug amphiphiles. Chem. Commun. 50, 6039\u20136042 (2014).","journal-title":"Chem. Commun."},{"key":"597_CR38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487\u2013502 (2017).","journal-title":"Cell"},{"key":"597_CR39","doi-asserted-by":"crossref","first-page":"e26403","DOI":"10.4161\/onci.26403","volume":"2","author":"L Spel","year":"2013","unstructured":"Spel, L., Boelens, J. J., Nierkens, S. & Boes, M. Antitumor immune responses mediated by dendritic cells: how signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology 2, e26403 (2013).","journal-title":"Oncoimmunology"},{"key":"597_CR40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"597_CR41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1158\/2326-6066.CIR-13-0123","volume":"2","author":"D Chandra","year":"2014","unstructured":"Chandra, D. et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2, 901\u2013910 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"597_CR42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/mt.2013.219","volume":"22","author":"C Devaud","year":"2014","unstructured":"Devaud, C. et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol. Ther. 22, 18\u201327 (2014).","journal-title":"Mol. Ther."},{"key":"597_CR43","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1073\/pnas.1801910115","volume":"115","author":"W Deng","year":"2018","unstructured":"Deng, W. et al. Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment. Proc. Natl Acad. Sci. USA 115, 8179\u20138184 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"597_CR44","doi-asserted-by":"crossref","first-page":"e26889","DOI":"10.4161\/onci.26889","volume":"2","author":"F Scrimieri","year":"2013","unstructured":"Scrimieri, F. et al. Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden. Oncoimmunology 2, e26889 (2013).","journal-title":"Oncoimmunology"},{"key":"597_CR45","first-page":"265","volume":"5","author":"RG van der Most","year":"2005","unstructured":"van der Most, R. G., Robinson, B. W. & Lake, R. A. Combining immunotherapy with chemotherapy to treat cancer. Discov. Med. 5, 265\u2013270 (2005).","journal-title":"Discov. Med."},{"key":"597_CR46","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/hed.24704","volume":"39","author":"SK Gadkaree","year":"2017","unstructured":"Gadkaree, S. K. et al. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model. Head Neck 39, 1086\u20131094 (2017).","journal-title":"Head Neck"},{"key":"597_CR47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biomaterials.2018.01.035","volume":"163","author":"DG Leach","year":"2018","unstructured":"Leach, D. G. et al. STINGel: controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy. Biomaterials 163, 67\u201375 (2018).","journal-title":"Biomaterials"},{"key":"597_CR48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nano.2017.10.013","volume":"14","author":"DR Wilson","year":"2018","unstructured":"Wilson, D. R. et al. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine 14, 237\u2013246 (2018).","journal-title":"Nanomedicine"},{"key":"597_CR49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","volume":"14","author":"Q Chen","year":"2019","unstructured":"Chen, Q. et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat. Nanotechnol. 14, 89\u201397 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"597_CR50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/540335a","volume":"540","author":"NA Peppas","year":"2016","unstructured":"Peppas, N. A. & Khademhosseini, A. Make better, safer biomaterials. Nature 540, 335\u2013336 (2016).","journal-title":"Nature"},{"key":"597_CR51","doi-asserted-by":"crossref","first-page":"eaaz8985","DOI":"10.1126\/sciadv.aaz8985","volume":"6","author":"F Wang","year":"2020","unstructured":"Wang, F. et al. Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. Sci. Adv. 6, eaaz8985 (2020).","journal-title":"Sci. Adv."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-020-0597-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-020-0597-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-020-0597-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T22:54:05Z","timestamp":1670280845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-020-0597-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1038\/s41551-020-0597-7","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}